Every 10-Q that Northrop Grumman Corp. (NOC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NOC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NOC filings page.
Northrop Grumman reported Q2 2026 sales of $10.9 billion, up 5% year over year, with net earnings of $1.09 billion and diluted EPS of $7.68, down 6% mainly because 2025 included a $231 million gain on the sale of its training services business and a larger pension FAS/CAS adjustment.
For the first six months, sales rose 5% to $20.8 billion, net earnings grew 19% to $2.0 billion, and diluted EPS increased 21% to $13.83, helped by stronger segment operating income and a sharply lower effective tax rate of 10.4% versus 17.5%, driven by research tax credits and remeasurement of uncertain tax positions.
Aeronautics led growth, with sales up 15% year to date and operating income rebounding as prior‑year B‑21 loss charges did not recur, though the B‑21 LRIP phase still carries about $2.0 billion in cumulative losses and a $1.0 billion remaining loss accrual. Defense Systems grew sales organically but margins compressed on unfavorable cost estimate changes for missile programs, including SiAW. Mission Systems expanded margins above 15%, while Space Systems margins were pressured by cost growth on solid rocket motor work.
Backlog reached $104.7 billion, with 35% expected to convert to revenue within 12 months. Operating cash flow was a use of $376 million year to date as working capital increased, while the company invested $469 million in capital expenditures, paid $684 million in dividends after a 7% per‑share increase, repurchased $68 million of stock and reduced long‑term debt by $527 million.
Northrop Grumman’s first quarter 2026 results show sharply higher profitability on modest sales growth. Sales rose 4% to $9.9 billion, while operating income jumped to $989 million from $573 million as operating margin expanded to 10.0% from 6.1%.
Net earnings increased 82% to $875 million and diluted EPS climbed to $6.14 from $3.32, helped by the absence of the large B‑21 loss charge recorded a year earlier and stronger segment performance, particularly in Aeronautics and Mission Systems.
Backlog remained very strong at $95.6 billion, with about 60% expected to turn into revenue within 24 months. Free cash flow was negative $1.8 billion, reflecting typical first‑half working capital usage and continued investment, including capacity expansion on the B‑21 program.
Northrop Grumman (NOC) reported Q3 2025 results with total sales of $10.423 billion, up modestly year over year, and diluted EPS of $7.67. Operating income was $1.242 billion as product sales rose, while service sales were steady. Segment performance was mixed: Mission Systems and Defense Systems grew operating income, while Aeronautics Systems and Space Systems faced program‑mix and cost dynamics.
The company recorded net EAC adjustments that included a $122 million unfavorable change on early B‑21 LRIP lots, largely offset by a loss contingency reduction tied to a contract restructure, and a $68 million favorable adjustment in restricted microelectronics. Year to date included a $231 million gain on the divestiture of training services. Backlog was $91.4 billion, with 40% expected as revenue over the next 12 months. Cash from operations was $860 million year to date, after working capital use on receivables and unbilled balances. The quarterly dividend increased 12% to $2.31 per share, and share repurchases totaled $1.168 billion year to date. As of October 16, 2025, 142,720,067 common shares were outstanding.